Neuro-Longevity Protocol

Protecting the Brain: The Most Critical Organ

The brain is the most metabolically active organ in the body, consuming 20% of total energy while comprising only 2% of body weight. This extreme metabolic demand makes it uniquely vulnerable to the cumulative effects of aging: oxidative stress, chronic neuroinflammation, neurotransmitter depletion, vascular compromise, and the accumulation of misfolded proteins including amyloid-beta and tau. Cognitive decline is not an inevitable consequence of aging but rather the result of identifiable, modifiable biological processes that begin decades before symptoms appear. The Neuro-Longevity Protocol intervenes at these early stages, establishing a comprehensive neuroprotective program that maintains cognitive peak performance while building resilience against neurodegenerative disease. For patients already experiencing cognitive symptoms, the protocol provides targeted intervention to stabilize and potentially reverse decline.

Mechanism of Action

The Neuro-Longevity Protocol targets the five primary drivers of brain aging. Neuroinflammation is addressed through microglial modulation using low-dose naltrexone (which shifts microglial phenotype from pro-inflammatory M1 to neuroprotective M2), anti-inflammatory peptides (Selank, BPC-157), and omega-3 fatty acid-derived specialized pro-resolving mediators. Neurotrophic support enhances brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression through the neuropeptides Semax and Selank, which cross the blood-brain barrier and directly upregulate neurotrophin gene expression, promoting synaptic plasticity, neurogenesis in the hippocampal dentate gyrus, and axonal repair. Mitochondrial neuroprotection, critical because neurons are post-mitotic and cannot dilute damaged mitochondria through cell division, is achieved through NAD+ restoration (activating neuronal SIRT3 for mitochondrial quality control), CoQ10, and PQQ (which promotes mitochondrial biogenesis). Cerebrovascular support optimizes blood-brain barrier integrity and cerebral perfusion through citicoline, vinpocetine, and endothelial function optimization. Amyloid and tau clearance is promoted through enhanced glymphatic function (sleep optimization) and autophagy activation (rapamycin, spermidine).

Therapeutics and Neuropeptides Used

Dr. Adin's neuro-longevity toolkit includes neuroprotective peptides as a cornerstone. Semax, a synthetic derivative of ACTH(4-10) with a Pro-Gly-Pro tail, enhances BDNF expression, improves cerebral circulation, and provides neuroprotection against ischemic and oxidative damage. Selank, derived from tuftsin with a Gly-Pro extension, modulates GABA and serotonin systems, reduces neuroinflammation, and enhances memory consolidation. Dihexa, a hexapeptide angiotensin IV analog, demonstrates extraordinary potency in promoting hepatocyte growth factor (HGF) signaling, which supports synaptic formation and maintenance. Low-dose naltrexone (1.5-4.5mg nightly) is used for microglial modulation and endorphin optimization. Pharmaceutical-grade lion's mane extract provides hericenones and erinacines that stimulate NGF synthesis. Citicoline (CDP-choline) supports phosphatidylcholine synthesis for neuronal membrane integrity and provides choline for acetylcholine production. Phosphatidylserine supports synaptic membrane fluidity and cortisol regulation. NAD+ infusions and NMN supplementation maintain neuronal energy metabolism and activate neuroprotective sirtuin pathways.

The Neuroscience of Cognitive Preservation

The scientific foundation for the Neuro-Longevity Protocol draws from decades of neuroscience research. The Bredesen Protocol (ReCODE), published in the journal Aging, demonstrated cognitive improvement in patients with mild cognitive impairment and early Alzheimer's disease through a multi-modal approach addressing 36 metabolic parameters, validating the systems-based approach to neurodegeneration. Research on BDNF published in Nature Reviews Neuroscience establishes this neurotrophin as essential for hippocampal long-term potentiation, the cellular mechanism of memory formation, and shows that BDNF levels decline with age and are further reduced by chronic stress and inflammation. Semax research from the Russian Academy of Sciences demonstrates enhanced cognitive function, improved cerebral blood flow, and neuroprotection against oxidative damage in both animal models and human clinical studies. The glymphatic system, discovered by Maiken Nedergaard's laboratory at the University of Rochester (published in Science, 2013), established that the brain clears metabolic waste including amyloid-beta primarily during deep sleep, providing the mechanistic basis for sleep optimization as a core neuroprotective intervention.

What the Patient Can Expect

The Neuro-Longevity Protocol begins with a comprehensive neurocognitive assessment including computerized cognitive testing (processing speed, working memory, executive function, verbal fluency), inflammatory and metabolic biomarkers relevant to brain health (hs-CRP, homocysteine, fasting insulin, HbA1c, omega-3 index, vitamin D), hormonal profiling (with particular attention to estradiol, testosterone, thyroid, and cortisol), genetic risk assessment (ApoE genotype, MTHFR status), and optional advanced neuroimaging. A personalized neuroprotective protocol is designed based on this comprehensive data set. Neuropeptide protocols typically produce noticeable improvements in mental clarity, focus, and verbal fluency within two to four weeks. Sleep optimization and stress management interventions improve cognitive energy and emotional resilience over four to eight weeks. Long-term neuroprotective benefits, including stabilized or improved cognitive testing scores and reduced inflammatory markers, are tracked through quarterly reassessment. The protocol is designed as a lifelong investment in cognitive health, evolving with new research and the patient's changing neurological needs.

References

1. Bredesen DE. "Reversal of cognitive decline: a novel therapeutic program." Aging, 2014;6(9):707-717.
2. Lu B, et al. "BDNF and synaptic plasticity, cognitive function, and dysfunction." Nature Reviews Neuroscience, 2013;14:7-23.
3. Ashmarin IP, et al. "Semax: a regulatory peptide with nootropic and neuroprotective properties." CNS Drug Reviews, 2005;11(1):17-26.
4. Xie L, et al. "Sleep drives metabolite clearance from the adult brain." Science, 2013;342(6156):373-377.
5. McCaffrey G, et al. "Dihexa promotes hepatocyte growth factor signaling and synaptic connectivity." Journal of Pharmacology and Experimental Therapeutics, 2014;349(1):23-33.